Ovoca Gold PLC (OVXA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovoca Gold PLC (OVXA) has a cash flow conversion efficiency ratio of -0.067x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-340.00K ≈ $-397.50K USD) by net assets (€5.06 Million ≈ $5.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OVXA market cap for the company's overall valuation and market capitalisation.
Ovoca Gold PLC - Cash Flow Conversion Efficiency Trend (1991–2023)
This chart illustrates how Ovoca Gold PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ovoca Gold PLC stock quote for real-time trading data and today's change.
Ovoca Gold PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovoca Gold PLC ranked by their cash flow conversion efficiency. Review Ovoca Gold PLC free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
New Energy Metals Corp
V:ENRG
|
0.045x |
|
WINDFALL GEOTEK
F:L7C2
|
0.592x |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
119.987x |
|
Bluejay Diagnostics Inc
NASDAQ:BJDX
|
-0.380x |
|
Colefax Group
LSE:CFX
|
0.297x |
|
Magnum Goldcorp Inc
V:MGI
|
0.167x |
|
Carr's Group plc
LSE:CARR
|
0.075x |
Annual Cash Flow Conversion Efficiency for Ovoca Gold PLC (1991–2023)
The table below shows the annual cash flow conversion efficiency of Ovoca Gold PLC from 1991 to 2023. Also see Ovoca Gold PLC asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €2.50 Million ≈ $2.92 Million |
€1.11 Million ≈ $1.30 Million |
0.446x | +165.91% |
| 2022-12-31 | €7.63 Million ≈ $8.93 Million |
€-5.16 Million ≈ $-6.04 Million |
-0.676x | -107.58% |
| 2021-12-31 | €13.43 Million ≈ $15.70 Million |
€-4.38 Million ≈ $-5.12 Million |
-0.326x | -186.35% |
| 2020-12-31 | €18.55 Million ≈ $21.69 Million |
€-2.11 Million ≈ $-2.47 Million |
-0.114x | -24.99% |
| 2019-12-31 | €23.84 Million ≈ $27.87 Million |
€-2.17 Million ≈ $-2.54 Million |
-0.091x | +33.83% |
| 2018-12-31 | €20.63 Million ≈ $24.11 Million |
€-2.84 Million ≈ $-3.32 Million |
-0.138x | -150.20% |
| 2017-12-31 | €22.40 Million ≈ $26.19 Million |
€-1.23 Million ≈ $-1.44 Million |
-0.055x | -227.60% |
| 2016-12-31 | €23.47 Million ≈ $27.44 Million |
€-394.00K ≈ $-460.63K |
-0.017x | -138.97% |
| 2015-12-31 | €21.45 Million ≈ $25.08 Million |
€924.00K ≈ $1.08 Million |
0.043x | +395.85% |
| 2014-12-31 | €22.46 Million ≈ $26.26 Million |
€-327.00K ≈ $-382.30K |
-0.015x | +86.58% |
| 2013-12-31 | €25.97 Million ≈ $30.37 Million |
€-2.82 Million ≈ $-3.29 Million |
-0.108x | -333.35% |
| 2012-12-31 | €48.62 Million ≈ $56.85 Million |
€2.26 Million ≈ $2.64 Million |
0.046x | -29.58% |
| 2011-12-31 | €50.15 Million ≈ $58.63 Million |
€3.31 Million ≈ $3.87 Million |
0.066x | +52.93% |
| 2010-12-31 | €56.75 Million ≈ $66.34 Million |
€2.45 Million ≈ $2.86 Million |
0.043x | -41.23% |
| 2009-12-31 | €46.42 Million ≈ $54.27 Million |
€3.41 Million ≈ $3.99 Million |
0.073x | +1163.67% |
| 2008-12-31 | €38.20 Million ≈ $44.66 Million |
€222.00K ≈ $259.54K |
0.006x | +117.38% |
| 2007-12-31 | €46.05 Million ≈ $53.84 Million |
€-1.54 Million ≈ $-1.80 Million |
-0.033x | -81.49% |
| 2006-12-31 | €30.83 Million ≈ $36.04 Million |
€-568.00K ≈ $-664.05K |
-0.018x | +57.83% |
| 2005-12-31 | €10.60 Million ≈ $12.39 Million |
€-463.00K ≈ $-541.30K |
-0.044x | +47.88% |
| 2004-12-31 | €4.41 Million ≈ $5.16 Million |
€-370.00K ≈ $-432.57K |
-0.084x | +13.55% |
| 2003-12-31 | €4.48 Million ≈ $5.23 Million |
€-434.00K ≈ $-507.39K |
-0.097x | -3503.35% |
| 2002-12-31 | €3.16 Million ≈ $3.69 Million |
€9.00K ≈ $10.52K |
0.003x | +105.19% |
| 2001-12-31 | €3.39 Million ≈ $3.96 Million |
€-186.00K ≈ $-217.45K |
-0.055x | -14.89% |
| 2000-12-31 | €3.14 Million ≈ $3.67 Million |
€-150.00K ≈ $-175.37K |
-0.048x | +18.22% |
| 1999-12-31 | €3.29 Million ≈ $3.84 Million |
€-192.00K ≈ $-224.47K |
-0.058x | +45.56% |
| 1998-12-31 | €3.29 Million ≈ $3.85 Million |
€-353.00K ≈ $-412.69K |
-0.107x | -325.41% |
| 1997-12-31 | €2.18 Million ≈ $2.55 Million |
€-55.00K ≈ $-64.30K |
-0.025x | +22.55% |
| 1996-12-31 | €1.93 Million ≈ $2.26 Million |
€-63.00K ≈ $-73.65K |
-0.033x | -2823.60% |
| 1994-12-31 | €1.79 Million ≈ $2.10 Million |
€-2.00K ≈ $-2.34K |
-0.001x | +96.94% |
| 1993-12-31 | €1.87 Million ≈ $2.18 Million |
€-68.00K ≈ $-79.50K |
-0.036x | -471.51% |
| 1992-12-31 | €1.12 Million ≈ $1.31 Million |
€11.00K ≈ $12.86K |
0.010x | +122.88% |
| 1991-12-31 | €1.12 Million ≈ $1.31 Million |
€-48.00K ≈ $-56.12K |
-0.043x | -- |
About Ovoca Gold PLC
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It's lead product is BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporate… Read more